Daiichi Sankyo

In October 2023, Northern TK Venture (NTK), a subsidiary of IHH Healthcare, had filed a claim against the Japanese pharmaceuticals manufacturer saying it caused losses to the company by preventing it from proceeding with open offers to buy a stake in Fortis Healthcare in 2018.

IHH hopes to soon float open offer for Fortis Healthcare, says its MD & CEO

The open offer could happen as early as this year. The Supreme Court’s final orders in the Daiichi Sankyo vs. Singh brothers case make no mention of the freeze on IHH-Fortis deal, suggest executives.

EX-promoters of Fortis Healthcare failed to purge themselves of contempt, says SC

The former promoters of Fortis Healthcare Ltd were facing a court battle after Daiichi had challenged the Fortis-IHH share deal to recover the Rs 3,600 crore arbitration award.

Fortis Healthcare shares drop 20% as Supreme Court orders status quo on IHH deal

The verdict further delays the takeover of the embattled hospital chain Fortis Healthcare by Malaysia’s IHH, which has already been pending for over three years.

SC likely to pronounce verdict on IHH open offer for Fortis tomorrow

Japanese drugmaker Daiichi Sankyo had challenged the Fortis-IHH deal to recover the Rs 3,600 crore arbitration award it had won in a Singapore tribunal against Fortis’ erstwhile promoters

Ranbaxy-Daiichi case: SC asks lenders to place loan records of Malvinder, Shivinder

The top court had earlier asked the Singh brothers to give it a plan as to how they would honour the arbitral award of Rs 3,500 crore granted by a Singapore tribunal against them and in favour of Japanese drug manufacturer Daiichi Sankyo.

AstraZeneca bets up to $6 billion on new Daiichi cancer drug

London-listed AstraZeneca said on Monday it would make an upfront payment of $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a newer class of treatments called antibody drug conjugates (ADC).

SC asks ex-Ranbaxy promoters to apprise it of complying with Rs 3,500 cr arbitral award

The top court asked the Singh brothers to consult their accountants as also financial and legal advisors and apprise it by March 28.

IHH puts Fortis open offer on hold, says seeking legal advice on SC's order

The proposed open offer is scheduled to be launched from December 18 to January 1, 2019.

Daiichi Sankyo says Singh brothers diverted Rs 2,900 crore through downstream companies

Daiichi filed three fresh applications in the high court saying that the brothers did not declare the money in their affidavits and it is parked in 25 different companies

Daiichi Sankyo moves NCLT to stay insolvency plea against RHC Holding

Daiichi Sankyo, which has filed an intervention application in the insolvency plea filed by HDFC Bank, said they have a decree to recover money against RHC Holding.

Daiichi arbitration case: Delhi High Court orders attachment of Singh brothers' declared assets

The court directed the Singh brothers to submit list of unencumbered personal assets and directed appointment of chartered accountant for valuation of those assets

Daiichi moves Delhi HC again to ban Fortis from selling stakes

Tension between Japanese drugmaker Daiichi Sankyo and Singh brothers of Fortis Healthcare is rising as the former has again moved the Delhi High Court against Fortis on March 6.

Daiichi case: HC asks Singh bros to declare value of total stake

In the long drawn court battle between Japanese drugmaker Daiichi Sankyo and the former Ranbaxy promoters Malvinder and Shivinder Singh, the Delhi High Court today ordered the Singh brothers to declare the value of their debt free shareholdings in various group companies by February 8.

Fortis stake sale: Delhi HC to hear Daiichi plea on Jan 23

Delhi High court will hear Daiichi Sankyo's plea against the Singh brothers on Januaury 23 after it moved the court to block the stake sale in Fortis Health. It claims that the sale would dilute assets and hamper recovery of damages for the 2008 sale of Ranbaxy.

Daiichi to shut down Indian R&D centre; 170 employees impacted

“Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline,” the company said in a statement.

Lupin shares rebound on USFDA nod for anti-hypertensive drug

Lupin shares recovered 2.5 percent from day's low to trade more than half a percent higher after getting approval from the US health regulator for antihypertensive drug.

Sun Pharma, Daiichi terminate transaction pacts

Daiichi Sankyo, Daiichi Sankyo (Thailand) Ltd, Sun Pharmaceutical Industries Ltd, Ranbaxy (Netherlands) BV and Ranbaxy (Thailand) Company Ltd entered into a termination agreement on May 26, 2016.

Govt to commission study on impact of FDI in pharma

The government is likely to commission a study soon to assess the impact of foreign direct investment in existing pharmaceutical companies in view of concerns expressed on the issue by a Parliamentary panel.

HSBC downgrades Indian equities to underweight

India remains one of the most over-owned market in Asia and the bank says the potential for more equity outflows has increased because foreign positions look stretched.

Rupee declines second straight week against USD

The rupee resumed lower at 62.54 per dollar as against the last weekend's level of 62.36 per dollar at the Interbank Foreign Exchange Market and dropped further a current year's low of 63.6450 before concluding at 63.56 per dollar, showing a loss of 120 paise or 1.92 percent.

Shanghvi did not buy Daiichi Sankyo's shares: Sun Pharma

The company was clarifying on speculations that Sanghvi, who holds 9.61 percent stake in Sun Pharma, had bought shares when Daiichi Sankyo exited from the Indian firm.

Sun Pharma gains 3%, JP Morgan overweight post massive fall

The brokerage believes base business of Sun Pharma can grow at 15 percent over the medium term, hence, sees significant upside from the integration of the Ranbaxy acquisition, manufacturing related synergies and the potential for accretive bolt-on M&A.

Sun Pharma plunges 11% as Daiichi Sankyo sells 8.9% stake

Daiichi Sankyo said it will make an announcement about the impact of any gain or loss on the sale of Sun Pharma shares when results for 2014-15 are announced.

Daiichi Sankyo to offload stake in Sun Pharma

As part of the deal, Ranbaxy shareholders were to receive 0.8 Sun Pharma shares for every Ranbaxy share they held. Daiichi Sankyo, which had acquired a majority stake in Ranbaxy in 2008 for around Rs 22,000 crore, held 63.4 percent in the Gurgaon-based firm at the time of the merger.